膿毒症診斷產品和市場趨勢

敗血症的診斷和治療是當今醫學實踐面臨的最大挑戰之一。在美國，每年約有170萬例敗血症病例，造成約270,000人死亡。敗血症是美國醫院治療的最昂貴的疾病之一。

敗血症的診斷並不容易。血培養分析仍然是標準的測試方法，儘管它既費時又費力。由於敗血症的複雜性及其與其他傳染病的複雜性，該領域包含了非常廣泛的產品和技術。

本報告分析了敗血症診斷技術和市場趨勢，包括當前的主要檢測方法及其優缺點，當前市場上的產品以及其他傳染性疾病（尤其是COVID-19）的概述。發生時，我們將收集並傳遞諸如此類的信息。

目錄

第1章執行摘要

• 概述
• 專業準則和定義
  • SIRS標準和敗血症1
  • 膿毒症2
  • 膿毒症3
  • 順序性（與膿毒症相關）器官衰竭（SOFA），qSOFA
• 市場考慮

第2章主機反應測試

• 降鈣素原（PCT）
  • 優勢
  • 缺點
• CRP
  • 優勢
  • 缺點
• 乳酸
• 細胞因子
• RNA，MRNA，MICRORNA（MIRNA）
• 腎上腺素（PROADM）
• D-二聚體
• 多標記方法

第3章病原體檢測/鑑定和抗菌藥敏試驗（AST）

• 多重分子測定
  • 用於膿毒症的多重分子檢測
• 質譜：一種流行的方法
  • 多種用於微生物鑑定/AST（抗菌物質敏感性測試）的產品

第4章冠狀病毒感染（COVID-19）和敗血症

• COVID-19與敗血症的耦合

第5章市場上主要的敗血症相關產品

The diagnosis and treatment of sepsis is one of the biggest challenges facing healthcare currently. In the United States, there are around 1.7 million cases of sepsis per year, resulting in approximately 270,000 deaths. Overall, the costs associated with sepsis make it the most expensive condition treated in US hospitals.

This report provides comprehensive information on products in the sepsis market, as well as:

• Sepsis Detection Practice Trends

• Sepsis Related Biomarkers: Advantages and Disadvantages

• Markets for Sepsis-Related Testing

• Mass Spectrometry and Sepsis

• COVID-19 and Sepsis

• Sepsis Testing Products on the Market (Grouped by Technology, POC, AST, Culture/ID, NGS, Host Response, amp-free isothermal or alt, Approval Status)

The diagnosis of sepsis is not straightforward. Blood culture analysis has remained a gold standard, despite the fact that it is typically slow and labor-intensive. The complexity of sepsis and the overlap with infectious diseases causes this field to comprise a very large range of products and technologies. This report takes into consideration the status of sepsis as a disease present within many other diseases. A special section on COVID-19 is included.

This report does cover many of the systems and products that diagnose infectious diseases, with an emphasis on rapid or multiplexed tests; but it does not provide a comprehensive breakdown of products for infectious disease detection. There is also a variety of other tests that are only touched upon, which also may be run depending on the appropriate action-blood gases, bilirubin, creatinine, platelets, etc.

Products from the following companies are considered in this report:

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

• OVERVIEW

• PROFESSIONAL GUIDELINES AND DEFINITIONS
  • SIRS Criteria and Sepsis-1
  • Sepsis-2
  • Sepsis-3
  • Sequential (Sepsis-related) Organ Failure (SOFA), qSOFA

• MARKET CONSIDERATIONS
  • Figure 1-1: Approximate Sepsis-Related Test Markets (CRP Market for All Applications, PCT Test Market for All Applications, Sepis-Purposed HAIs)

CHAPTER 2: TESTING OF HOST RESPONSE

• Table 2-1: Top Biomarkers Used in Sepsis

• PROCALCITONIN (PCT)
  • Advantages
  • Disadvantages

• CRP
  • Advantages
  • Disadvantages

• LACTATE
• CYTOKINES
• RNA, MRNA, MICRORNA (MIRNA)
• PROADRENOMEDULLIN (PROADM)
• D-DIMER
• MULTI-MARKER APPROACHES

CHAPTER 3: PATHOGEN DETECTION/ IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TESTING

• MULTIPLEX MOLECULAR ASSAYS
  • Multiplex Molecular Assays Used for Sepsis
    • Table 3-1: Multiplex Molecular Assays Used for Sepsis

• MASS SPECTROMETRY ACHIEVING POPULARITY
  • Wide Selection of Products for Microbe ID, AST
    • Table 3-2: Selected Mass Spectrometry Products Used for Microbial ID and AST
    • Table 3-3: Systems and Products for Bacterial Culture, Staining, Incubation

CHAPTER 4: COVID-19 AND SEPSIS

• COVID-19 AND OVERLAP WITH SEPSIS

CHAPTER 5: MAJOR SEPSIS-RELATED PRODUCTS ON THE MARKET

• Table 5-1: Sepsis Products on the Market